Sign In
Buy NPCE
$12.89
-0.86 (-6.25%)
At Close: Jul 31, 2026
NeuroPace Q1 Earnings Call Highlights
09:09pm, Tuesday, 12'th May 2026
NeuroPace NASDAQ: NPCE raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution acros
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Tuesday, 12'th May 2026
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.21 per share a year ago.
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
04:05pm, Tuesday, 12'th May 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
10:36am, Thursday, 07'th May 2026
NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a majo
NeuroPace (NASDAQ:NPCE) & Advanced Biomedical Technologies (OTCMKTS:ABMT) Head to Head Survey
02:14am, Friday, 24'th Apr 2026
NeuroPace (NASDAQ: NPCE - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get Free Report) are both medical companies, but which is the superior business? We will contrast the tw
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
04:05pm, Friday, 10'th Apr 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t
Contrasting NeuroPace (NASDAQ:NPCE) & Integer (NYSE:ITGR)
02:17am, Sunday, 05'th Apr 2026
Integer (NYSE: ITGR - Get Free Report) and NeuroPace (NASDAQ: NPCE - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
12:31pm, Thursday, 02'nd Apr 2026
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
12:26pm, Thursday, 02'nd Apr 2026
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
10:56am, Thursday, 02'nd Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the posi
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:43am, Wednesday, 01'st Apr 2026
NeuroPace, Inc. (NASDAQ: NPCE - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rat
NPCE RNS System Explained: Growth Drivers and Setup for 2026
12:41pm, Tuesday, 10'th Mar 2026
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
12:41pm, Tuesday, 10'th Mar 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
12:27pm, Tuesday, 10'th Mar 2026
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
